Silvia Ulrich, Prof. Dr.
University Hospital Zurich, Department of Pulmonology
8
8
7
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
No phase data
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Talant M Sooronbaev, Prof. Dr.
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Shared therapeutic areas:
Worked with same sponsors:
Talant MA Sooronbaev, Prof. Dr.
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Shared therapeutic areas:
Worked with same sponsors:
Mohamed AbdElmoniem
Lecturer of chest medicine faculty of medicine Mansoura university
Shared therapeutic areas:
Meral Boşnak Güçlü, Prof. Dr.
Gazi University
Shared therapeutic areas:
Konrad E Bloch, MD
University Hospital, Zürich
Shared therapeutic areas:
Worked with same sponsors:
Ashika Ahmed, MD
Bellerophon Therapeutics
Shared therapeutic areas:
Russel Hirsch, MD
Children's Hospital Medical Center, Cincinnati
Shared therapeutic areas:
Talant M Sooronbaev, MD
National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Shared therapeutic areas:
Worked with same sponsors:
Meral Boşnak Güçlü, PhD
Gazi University
Shared therapeutic areas:
Ebru Calik Kutukcu, PhD
Hacettepe University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), 6MWT Assessed at High Altitude (3200m) vs Low Altitude (760m)
High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)
High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m)
Highlanders With High Altitude Pulmonary Hypertension (HAPH), 6 Minute Walk Distance (6MWD) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
Highlanders With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Arterial Pressure (PAP) Assessed at 3200m With and Without Supplemental Oxygen Therapy (SOT)
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy With Chronic Lung Diseases
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)
HAPH Registry: Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.
All 8 trials loaded